Optimizerx Corp (OPRX) Stock Price & Analysis
Optimizerx Corp (OPRX) rose 0.40% to USD 5.07 as of June 10, 2026 at 08:39 UTC, according to Nexqual real-time market data.
OPRX last closed at USD 5.05; the session ranged USD 4.92–5.31 on volume of 305,778 shares. Market capitalization is $95.14M, with a 52-week range of USD 4.57–22.25 (NCM). Source: Nexqual, June 10, 2026 at 08:39 UTC.
Key Statistics (as of June 10, 2026 at 08:39 UTC)
| Price | USD 5.07 |
|---|---|
| Change | ▲ 0.40% (up) |
| Previous Close | USD 5.05 |
| Open | USD 5.11 |
| Day Range | USD 4.92 – 5.31 |
| 52-Week Range | USD 4.57 – 22.25 |
| Volume | 305,778 shares |
| Market Cap | $95.14M |
| Exchange | NCM |
Technical Analysis (OPRX)
Nexqual's technical model rates OPRX "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.09 (neutral) |
| vs SMA50 | Below (USD 5.99) |
| MACD | -0.28 (negative) |
Analyst Ratings (OPRX)
Wall Street analysts rate OPRX "None" based on 6 analysts, with a mean price target of USD 11.5 (range USD 7–18), per Nexqual as of June 10, 2026 at 08:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 11.5 |
| High Target | USD 18 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (OPRX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.1 |
| Revenue Estimate | $20.19M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 0.51 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.2 vs est 0.04 ▲ beat |
| 2025-06-30 | USD 0.24 vs est 0.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:39 UTC.
Financials & Fundamentals (OPRX)
| Total Revenue | $107.34M |
|---|---|
| Revenue Growth (YoY) | -9.50% |
| Gross Margin | +70.04% |
| Operating Margin | +2.00% |
| Profit Margin | +6.37% |
| ROE | +5.56% |
| Debt / Equity | 18.3 |
| Current Ratio | 5.37 |
| Total Cash | $20.17M |
| Total Debt | $23.72M |
| Free Cash Flow | $11.35M |
Source: Nexqual, June 10, 2026 at 08:39 UTC.
Financial Health Score (OPRX)
Nexqual rates Optimizerx Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 08:39 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 70%, operating 2% |
| Balance Sheet | Strong — $20M cash vs $24M debt |
| Cash Flow | Solid — FCF $11M, 10% margin |
| Efficiency | Mixed — ROE 6%, ROA 5.4% |
Ownership (OPRX)
| Insider Ownership | +11.79% |
|---|---|
| Institutional Ownership | +77.73% |
| Shares Outstanding | 18.77M |
| Float | 14.48M |
| Short % of Float | +9.67% |
Source: Nexqual, June 10, 2026 at 08:39 UTC.
Leadership (OPRX)
Optimizerx Corp is led by Stephen L. Silvestro (age 47), CEO & Director, per Nexqual as of June 10, 2026 at 08:39 UTC.
| CEO & Director | Stephen L. Silvestro (age 47) |
|---|---|
| Chief Financial & Strategic Officer | Edward Stelmakh C.M.A. (age 59) |
| Chief Operating Officer | Brendan Merrell (age 40) |
| Chief Product Officer & CTO | Doug Besch (age 43) |
Major Backers & Investors (OPRX)
Notable institutional backers of Optimizerx Corp include Whetstone Capital Advisors, LLC, Royce & Associates LP, Parkman Healthcare Partners LLC, according to Nexqual as of June 10, 2026 at 08:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Whetstone Capital Advisors, LLC | 12.47% |
| Royce & Associates LP | 7.34% |
| Parkman Healthcare Partners LLC | 6.03% |
| Kennedy Capital Management, LLC | 5.43% |
| CALAMOS INVESTMENT TRUST/IL-Calamos Timpani Small Cap Growth Fund | 5.34% |
| BLAIR WILLIAM & CO/IL | 5.08% |
| Rice, Hall, James & Associates LLC | 4.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.86% |
| Vanguard Group | 11.22% |
| Dimensional Fund Advisors | 4.66% |
Source: Nexqual, June 10, 2026 at 08:39 UTC.
From Optimizerx Corp's Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- OptimizeRx Corporation operates as a digital healthcare technology company.
- The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JYNT | The Joint Corp. | USD 8.41 | ▲ 1.45% |
| QTRX | Quanterix Corporation | USD 3.09 | ▼ 6.36% |
| SIBN | SI-BONE, Inc. | USD 15.53 | ▲ 2.71% |
| ORGO | Organogenesis Holdings Inc. | USD 2.48 | ▲ 2.48% |
| HCAT | Health Catalyst, Inc | USD 1.71 | ▼ 11.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:39 UTC. This page is informational and not investment advice.